These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25086830)

  • 1. Distribution of venlafaxine and O-desmethylvenlafaxine in a fatal case.
    Vignali C; Morini L; Chen Y; Stramesi C; Groppi A
    Forensic Sci Int; 2014 Sep; 242():e48-e51. PubMed ID: 25086830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.
    Jornil J; Nielsen TS; Rosendal I; Ahlner J; Zackrisson AL; Boel LW; Brock B
    Forensic Sci Int; 2013 Mar; 226(1-3):e26-31. PubMed ID: 23332809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two fatal cases of venlafaxine poisoning.
    Parsons AT; Anthony RM; Meeker JE
    J Anal Toxicol; 1996; 20(4):266-8. PubMed ID: 8835666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of analytical methods in the determination of two venlafaxine fatalities.
    Long C; Crifasi J; Maginn D; Graham M; Teas S
    J Anal Toxicol; 1997; 21(2):166-9. PubMed ID: 9083836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions.
    Launiainen T; Rasanen I; Vuori E; Ojanperä I
    Int J Legal Med; 2011 May; 125(3):349-58. PubMed ID: 20432045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid high-performance liquid chromatographic measurement of venlafaxine and O-desmethylvenlafaxine in human plasma. Application to management of acute intoxications.
    Matoga M; Pehourcq F; Titier K; Dumora F; Jarry C
    J Chromatogr B Biomed Sci Appl; 2001 Sep; 760(2):213-8. PubMed ID: 11530979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postmortem tissue concentrations of venlafaxine.
    Goeringer KE; McIntyre IM; Drummer OH
    Forensic Sci Int; 2001 Sep; 121(1-2):70-5. PubMed ID: 11516890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics of venlafaxine when given in a twice-daily regimen.
    Troy SM; Parker VD; Fruncillo RJ; Chiang ST
    J Clin Pharmacol; 1995 Apr; 35(4):404-9. PubMed ID: 7650231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Acute lethal poisoning with venlafaxine].
    Szpak D; Ciszowski K; Gawlikowski T; Krzyzanowska-Kierepka E
    Przegl Lek; 2010; 67(8):628-9. PubMed ID: 21387792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism.
    Paulzen M; Haen E; Hiemke C; Fay B; Unholzer S; Gründer G; Schoretsanitis G
    J Affect Disord; 2018 Feb; 227():506-511. PubMed ID: 29156365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics.
    Klamerus KJ; Parker VD; Rudolph RL; Derivan AT; Chiang ST
    Pharmacotherapy; 1996; 16(5):915-23. PubMed ID: 8888087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fatal case of venlafaxine overdose.
    Bosse GM; Spiller HA; Collins AM
    J Med Toxicol; 2008 Mar; 4(1):18-20. PubMed ID: 18338306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic interaction between multiple-dose venlafaxine and single-dose lithium.
    Troy SM; Parker VD; Hicks DR; Boudino FD; Chiang ST
    J Clin Pharmacol; 1996 Feb; 36(2):175-81. PubMed ID: 8852394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype.
    Mannheimer B; Haslemo T; Lindh JD; Eliasson E; Molden E
    Ther Drug Monit; 2016 Feb; 38(1):127-34. PubMed ID: 26418700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: exploring predictive biomarkers for treatment outcomes.
    Jiang F; Kim HD; Na HS; Lee SY; Seo DW; Choi JY; Ha JH; Shin HJ; Kim YH; Chung MW
    Psychopharmacology (Berl); 2015 Jun; 232(11):1899-909. PubMed ID: 25510856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alternative venlafaxine kinetics in overdose.
    Langford NJ; Martin U; Ruprah M; Ferner RE
    J Clin Pharm Ther; 2002 Dec; 27(6):465-7. PubMed ID: 12472987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum and Saliva Concentrations of Venlafaxine, O-Desmethylvenlafaxine, Quetiapine, and Citalopram in Psychiatric Patients.
    Ebert K; Maurice E; Lukačin R; Fleischhaker C; Schulz E; Ebert D; Clement HW
    Ther Drug Monit; 2018 Jun; 40(3):351-355. PubMed ID: 29746434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP2D6 genotype on the disposition of the enantiomers of venlafaxine and its major metabolites in postmortem femoral blood.
    Kingbäck M; Karlsson L; Zackrisson AL; Carlsson B; Josefsson M; Bengtsson F; Ahlner J; Kugelberg FC
    Forensic Sci Int; 2012 Jan; 214(1-3):124-34. PubMed ID: 21840145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatal venlafaxine overdose with acinar zone 3 liver cell necrosis.
    Shaw MW; Sheard JD
    Am J Forensic Med Pathol; 2005 Dec; 26(4):367-8. PubMed ID: 16304474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic/pharmacodynamic modelling of venlafaxine: pupillary light reflex as a test system for noradrenergic effects.
    Lindauer A; Siepmann T; Oertel R; Jung A; Ziemssen T; Jaehde U; Kirch W; Siepmann M
    Clin Pharmacokinet; 2008; 47(11):721-31. PubMed ID: 18840027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.